Skip to main content

and
  1. No Access

    Article

    Estimating the Health Effects of Expansions in Health Expenditure in Indonesia: A Dynamic Panel Data Approach

    The marginal productivity of a country’s healthcare system refers to the health gains produced per unit change in the level of spending. In budget-constrained settings, this metric reflects the opportunity cos...

    Silvia Moler-Zapata, Noémi Kreif in Applied Health Economics and Health Policy (2022)

  2. Article

    Open Access

    Supporting a review of the benefits package of the National Health Insurance Scheme in Ghana

    Although Ghana is lauded for its National Health Insurance Scheme (NHIS), concerns exist about the scheme’s functioning and sustainability. An often-cited issue—contributing to the scheme’s decreasing membersh...

    Heleen Vellekoop, Emmanuel Odame in Cost Effectiveness and Resource Allocation (2022)

  3. No Access

    Article

    Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment

    Despite being a fundamental tenet of economic analysis there is a lack of clarity regarding the relevance of opportunity costs to cost-effectiveness analysis for health technology assessment. We argue that thi...

    James Lomas, Jessica Ochalek, Rita Faria in Applied Health Economics and Health Policy (2022)

  4. Article

    Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates

    Many health technology assessment committees have an explicit or implicit reference value (often referred to as a ‘threshold’) below which new health technologies or interventions are considered value for mone...

    Laura C. Edney, James Lomas, Jonathan Karnon, Laura Vallejo-Torres in PharmacoEconomics (2022)

  5. No Access

    Article

    Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach

    Health technology assessment has been increasingly used in China, having been legally mandated in 2019, to inform reimbursement decisions and price negotiations between the National Healthcare Security Adminis...

    Jessica Ochalek, Haiyin Wang, Yuanyuan Gu, James Lomas, Henry Cutler in PharmacoEconomics (2020)

  6. Article

    Open Access

    A one stop shop for cost-effectiveness evidence? Recommendations for improving Disease Control Priorities

    Setting out a health benefits package (HBP) of interventions to be prioritised for funding is an important step towards achieving universal health coverage in low and middle income countries. The 3rd version o...

    Matthias Arnold, Susan Griffin in Cost Effectiveness and Resource Allocation (2019)

  7. No Access

    Article

    Cost-Effectiveness Thresholds: the Past, the Present and the Future

    Cost-effectiveness (CE) thresholds are being discussed more frequently and there have been many new developments in this area; however, there is a lack of understanding about what thresholds mean and their imp...

    Praveen Thokala, Jessica Ochalek, Ashley A. Leech, Thaison Tong in PharmacoEconomics (2018)